Original article (Clinical research)

Analysis of clinical characteristics of 198 cases of diffuse large B cell lymphoma and affecting factors of prognosis

  • XU Hai-yan ,
  • ZHANG Feng-chun ,
  • LIN Yu-mei
Expand
  • 1.Department of Haematological Oncology, Kowloon Hospital, Shanghai Jiao Tong University School of Medicine, Suzhou 215021, China; 2.Department of Oncology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200025, China; 3.Department of Oncology, China-Japan Union Hospital of Jilin University, Changchun 130033, China

Online published: 2014-12-02

Abstract

Objective To investigate the clinical characteristics of diffuse large B cell lymphoma (DLBCL) and affecting factors of the prognosis. Methods A total of 198 patients initially diagnosed as DLBCL were selected. The general clinical characteristics, immunological subtypes, and expressions of CD5, Bcl-2, and Ki-67 were analyzed to determine the relationship of relevant factors and prognosis. Results Among 161 patients received immunological detection, the incidence of non-germinal center B cell (non-GCB) type DLBCL (67.08%) was significantly higher than that of germinal center B cell (GCB) type DLBCL (32.92%). Positive expression rate of Bcl-2 in 134 patients was 73.88%, while positive expression rate of CD5 in 84 patients was 19.05%. The Ki-67 expression of 92.73% of 165 patients was higher than 50%. The differences of clinical characteristics and expressions of CD5, Bcl-2, and Ki-67 of patients with GCB type DLBCL and non-GCB type DLBCL were not statistically significant (P>0.05). The survival time of patients with DLBCL was affected by the age, B symptom, PS score, clinical stage, lactate dehydrogenase (LDH) level, international prognostic index (IPI), immunological subtype, CD5, and treatment by rituximab. PS score, IPI, immunological subtype, and treatment by rituximab were independent factors that affected the prognosis of DLBCL. Conclusion The origin of DLBCL tumor cells has no correlation with clinical characteristics. PS score, IPI, immunological subtype, and treatment by rituximab are independent factors that affect the prognosis of patients with DLBCL.

Cite this article

XU Hai-yan , ZHANG Feng-chun , LIN Yu-mei . Analysis of clinical characteristics of 198 cases of diffuse large B cell lymphoma and affecting factors of prognosis[J]. Journal of Shanghai Jiao Tong University (Medical Science), 2014 , 34(11) : 1618 . DOI: 11.3969/j.issn.1674-8115.2014.11.012

Outlines

/